Collectively, these results suggest that stratification of GC patients by IGF1 and NEDD4 is necessary, and targeting NEDD4 may be an alternative or combined strategy to address the susceptibility and drug resistance of IGF1 signaling targeted therapy. Here, NEDD4 is linked to gastric cancer.